{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:54:44Z","timestamp":1792000484151,"version":"4.4.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The tryptophan-degrading enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a plastic immune checkpoint molecule that potently orchestrates immune responses within the tumor microenvironment (TME). As a heme-containing protein, IDO1 catalyzes the conversion of the essential amino acid tryptophan into immunoactive metabolites, called kynurenines. By depleting tryptophan and enriching the TME with kynurenines, IDO1 catalytic activity shapes an immunosuppressive TME. Accordingly, the inducible or constitutive IDO1 expression in cancer correlates with a negative prognosis for patients, representing one of the critical tumor-escape mechanisms. However, clinically trialed IDO1 catalytic inhibitors disappointed the expected anti-tumor efficacy. Interestingly, the non-enzymatic apo-form of IDO1 is still active as a transducing protein, capable of promoting an immunoregulatory phenotype in dendritic cells (DCs) as well as a pro-tumorigenic behavior in murine melanoma. Moreover, the IDO1 catalytic inhibitor epacadostat can induce a tolerogenic phenotype in plasmacytoid DCs, overcoming the catalytic inhibition of IDO1. Based on this recent evidence, IDO1 plasticity was investigated in the human ovarian cancer cell line, SKOV-3, that constitutively expresses IDO1 in a dynamic balance between the holo- and apo-protein, and thus potentially endowed with a dual function (i.e., enzymatic and non-enzymatic). Besides inhibiting the catalytic activity, epacadostat persistently stabilizes the apo-form of IDO1 protein, favoring its tyrosine-phosphorylation and promoting its association with the phosphatase SHP-2. In SKOV-3 cells, both these early molecular events activate a signaling pathway transduced by IDO1 apo-protein, which is independent of its catalytic activity and contributes to the tumorigenic phenotype of SKOV-3 cells. Overall, our findings unveiled a new mechanism of action of epacadostat on IDO1 target, repositioning the catalytic inhibitor as a stabilizer of the apo-form of IDO1, still capable of transducing a pro-tumorigenic pathway in SKOV-3 tumor. This mechanism could contribute to clarify the lack of effectiveness of epacadostat in clinical trials and shed light on innovative immunotherapeutic strategies to tackle IDO1 target.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1346686","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:32:35Z","timestamp":1706157155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells"],"prefix":"10.3389","volume":"15","author":[{"given":"Sofia","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Belladonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Pallotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Panfili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Suvieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Macchiarulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Mondanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciriana","family":"Orabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690112","article-title":"Cancer immunotherapies: from efficacy to resistance mechanisms - not only checkpoint matters","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020787","article-title":"Decoding the complex crossroad of tryptophan metabolic pathways","volume":"23","author":"Mondanelli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.immuni.2022.05.013","article-title":"Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication","volume":"55","author":"Gargaro","year":"2022","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01665","article-title":"Structure and plasticity of indoleamine 2,3-dioxygenase 1 (IDO1)","volume":"64","author":"R\u00f6hrig","year":"2021","journal-title":"J Med Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2012.00029","article-title":"Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase","volume":"18","author":"Orabona","year":"2012","journal-title":"Mol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201949756","article-title":"Class IA PI3Ks regulate subcellular and functional dynamics of IDO1","volume":"21","author":"Iacono","year":"2020","journal-title":"EMBO Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810278105","article-title":"SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis","volume":"105","author":"Orabona","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e85872","DOI":"10.7554\/eLife.85872","article-title":"A back-door insight into the modulation of Src kinase activity by the polyamine spermidine","volume":"30","author":"Rossini","year":"2023","journal-title":"eLife"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216236","article-title":"Membrane localization and phosphorylation of indoleamine 2,3-dioxygenase 2 (IDO2) in A549 human lung adenocarcinoma cells: first steps in exploring its signaling function","volume":"24","author":"Suvieri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12954","article-title":"Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1","volume":"21","author":"Albini","year":"2017","journal-title":"J Cell Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2170095","article-title":"The signaling function of IDO1 incites the Malignant progression of mouse B16 melanoma","volume":"12","author":"Orecchini","year":"2023","journal-title":"Oncoimmunology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.360.6389.588","article-title":"A new cancer immunotherapy suffers a setback","volume":"360","author":"Garber","year":"2018","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma","volume":"4","author":"Van den Eynde","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1134551","article-title":"The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1","volume":"14","author":"Panfili","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neuropharm.2015.10.036","article-title":"Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells","volume":"102","author":"Volpi","year":"2016","journal-title":"Neuropharmacology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1210-1248","article-title":"Towards a knowledge-based human protein atlas","volume":"28","author":"Uhlen","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.molcel.2022.02.007","article-title":"Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling","volume":"82","author":"Fiore","year":"2022","journal-title":"Mol Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102509","article-title":"A novel mutation of indoleamine 2,3-dioxygenase 1 causes a rapid proteasomal degradation and compromises protein function","volume":"115","author":"Mondanelli","year":"2020","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.10.033","article-title":"Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1","volume":"158","author":"Albini","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12618","article-title":"Functions of shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J Cell Mol Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","article-title":"The tyrosine phosphatase Shp2 in development and cancer","volume":"106","author":"Grossmann","year":"2010","journal-title":"Adv Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S138833","article-title":"SHP2 overexpression enhances the invasion and metastasis of ovarian cancer","volume":"10","author":"Hu","year":"2017","journal-title":"Vitro vivo. Onco Targets Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000492849","article-title":"The clinicopathological and prognostic significance of IDO1 expression in human solid tumors: evidence from a systematic review and meta-analysis","volume":"49","author":"Yu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00034","article-title":"Tryptophan-degrading enzymes in tumoral immune resistance","volume":"6","author":"van Baren","year":"2015","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16086","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme","volume":"289","author":"Pallotta","year":"2022","journal-title":"FEBS J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"20160523","DOI":"10.1098\/rstb.2016.0523","article-title":"Protein moonlighting: what is it, and why is it important","volume":"373","author":"Jeffery","year":"2018","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613069","article-title":"Moonlighting proteins are important players in cancer immunology","volume":"11","author":"Adamo","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2022.01.008","article-title":"Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through GAPDH- and Hsp90-dependent control of their heme levels","volume":"180","author":"Biswas","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00771","article-title":"Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma","volume":"65","author":"Bollu","year":"2022","journal-title":"J Med Chem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1346686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:32:39Z","timestamp":1706157159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1346686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2024.1346686"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1346686","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"article-number":"1346686"}}